Just been digging through some interesting plays in the sub-$10 space and honestly, there's more going on there than most people realize. Everyone talks about mega-cap tech, but if you're actually trying to find dollar stocks that will explode, you've got to look at where the fundamentals are actually improving.

So here's the thing about cheap stocks under $10 - most traders dismiss them outright, but that's actually where you find the real opportunities if you know what to look for. The key is filtering for companies that aren't just cheap on price, but actually have improving earnings outlooks and analyst conviction behind them. I'm talking about stocks where multiple analysts are raising estimates, not cutting them.

Let me walk you through what I've been screening for. You want volume so you can actually get in and out. You want analyst coverage because that means institutional eyes are on it. And most importantly, you want positive earnings revisions - that's the signal that something's actually changing at the company level.

That's what caught my attention with Amicus Therapeutics (FOLD). This is a biotech company focused on rare diseases - Fabry disease, Pompe disease, that kind of specialized medicine space. What's interesting is they just hit GAAP profitability in Q3, which is a big deal for a biotech. Revenue grew 17% that quarter, and they're onboarding more patients with their key drugs.

Here's where it gets compelling: the projections show 19% revenue growth through 2026, hitting around $745 million. But the bottom line is where you see the real inflection - they're expecting earnings to jump 50% this year and then 87% next year. That's the kind of acceleration you want to see in dollar stocks that will explode. We're talking about going from $0.24 per share in 2024 to $0.67 projected for 2026.

The analyst consensus is pretty bullish too. Most of the coverage is "Strong Buy," and the price target suggests 61% upside from where it was trading. FOLD already moved 60% over the prior six months, so it's not like this is some hidden gem nobody's noticed - but the momentum and the fundamentals actually line up here.

What I find most interesting about screening the sub-$10 space right now is that you're finding situations where the market hasn't fully priced in the earnings growth yet. Biotech especially has been beaten down, so when you find one actually executing and hitting profitability milestones, that's worth paying attention to. The combination of positive revisions, analyst upgrades, and actual business inflection is what separates the real opportunities from the noise in cheap stocks.

If you're building a portfolio and looking for growth, this is the kind of name worth having on your radar. Not everything under $10 is worth owning, but when the fundamentals actually improve this sharply, that's when dollar stocks that will explode tend to make their moves.